Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v7-FR
Language English French
Date Updated 2022-01-20 2022-01-07
Drug Identification Number 00027243 00027243
Brand name DIHYDROERGOTAMINE (DHE), 1MG/ML DIHYDROERGOTAMINE (DHE), 1MG/ML
Common or Proper name DIHYDROERGOTAMINE MESYLATE INJECTION USP (DHE) DIHYDROERGOTAMINE MESYLATE INJECTION USP (DHE)
Company Name STERIMAX INC STERIMAX INC
Ingredients DIHYDROERGOTAMINE MESYLATE DIHYDROERGOTAMINE MESYLATE
Strength(s) 1MG 1MG
Dosage form(s) LIQUID LIQUID
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 5 AMPOULES 5 AMPOULES
ATC code N02CA N02CA
ATC description ANTIMIGRAINE PREPARATIONS ANTIMIGRAINE PREPARATIONS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2021-11-01 2021-11-01
Actual start date
Estimated end date 2022-01-17 2022-01-17
Actual end date 2022-01-19
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments One-time allocation of remaining stock will be available at McKesson on November 1st. One-time allocation of remaining stock will be available at McKesson on November 1st.
Health Canada comments